Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin In Dravet Syndrome; First Sites Activated With A Number Of Additional Rapid-Start Sites Being Activated In The Coming Weeks
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals has initiated a Phase 3 study for its drug Bexicaserin, targeting seizures in Dravet syndrome. The study has begun with initial sites activated and more to follow soon.
September 26, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Longboard Pharmaceuticals has started a Phase 3 study for Bexicaserin, targeting Dravet syndrome. This marks a significant step in their drug development process, potentially impacting their market position.
The initiation of a Phase 3 study is a critical milestone in drug development, indicating progress towards potential market approval. This can positively influence investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100